123 SN Test
Published: December 09, 2025
- Reaffirmed: This 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline has been reviewed and determined to be current as of May 2025. See the 2025 AHA/ACC Methodology and Policies Manual (PDF) for information on reaffirmation.
- Hypertrophic Cardiomyopathy (HCM) remains a common genetic heart disease in populations throughout the world.
- The prevalence of unexplained asymptomatic hypertrophy in young adults in the United States has been reported at about 1:500. Symptomatic hypertrophy based on medical claims data has been estimated at <1:3000 adults in the United States